Novel targets for antiinflammatory and antiarthritic agents

Current Pharmaceutical Design

Volumn 12, Issue 19, 2006, Pages 2437-2454

  Kulkarni, R G ^a   Achaiah, G ^a   Sastry, G Narahari ^b  

^a KAKATIYA UNIVERSITY   (India)

^b INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

IL 1; Inflammation; Matrix metalloproteinase; p38 Kinase; TNF

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; ACETYLSALICYLIC ACID; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; ARACHIDONIC ACID DERIVATIVE; BARBITURIC ACID DERIVATIVE; BATIMASTAT; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; FENAMIC ACID DERIVATIVE; I KAPPA B; ILOMASTAT; INTERLEUKIN 1; LENALIDOMIDE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; SALICYLATE SODIUM; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TANOMASTAT; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; CANCER; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; ENTERITIS; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATORY DISEASE; NAUSEA AND VOMITING; NONHUMAN; OSTEOARTHRITIS; PEPTIC ULCER; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STOMACH HEMORRHAGE; STOMACH ULCER; STRUCTURE ACTIVITY RELATION; SYSTEMATIC REVIEW; THROMBOSIS;

ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MODELS, BIOLOGICAL;

EID: 33745740053     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777698945     Document Type: Review

References (269)

1. Golydne ME, Burrish GF, Poubelle P, Borgeat P. Arachidonic acid metabolism among human mononuclear leukocytes. Lipoxygenase-related pathways. J Biol Chem 1984; 259: 8815-19.
2. Garner A. Adaptation in the pharmaceutical industry, with particular reference to gastrointestinal drugs and diseases. Scand J Gastroenterol 1992; 27: 83-89.
3. Vane JR. Nat. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-35.
4. Samuelsson B, Dahle'n SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237: 1171-76.
5. Ford-Hutchinson AW. Leukotrienes: their formation and role as inflammatory mediators. Fed Proc 1985; 44: 25-9.
6. Busse W, Gaddy JN. The role of leukotriene antagonists and inhibitors in the treatment of airway disease. Am Rev Respir Dis 1991; 143: S103-07.
7. Chung KF. Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Eur Respir J 1995; 8:1203-13.
8. Vane JR, Botting RM. Mechanism of action of antiinflammatory drugs. Scand J Rheumatol 1996; 25: 9-12.
9. Furst D. Pharmacology and efficacy of cyclooxygenase (COX) inhibitors. Am J Med 1999; 107: 18s-22s.
10. Catella-Lawson F, Crofford LJ. Cyclooxygenase inhibition and thrombogenicity Am J Med 2001; 110: 28S-32S.
11. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55.
12. McMurray RW, Hardy KJ. COX-2 inhibitors: today and tomorrow. Am J Med Sci 2002; 323: 181-89.
13. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N EngI J Med 2000; 343: 1520-1528.
14. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal antiinflammatory drugs and risk of serious coronary heart Disease. Lancet 2002; 360: 1071-73.
15. Kemp JP. Recent advances in the management of asthma using leukotriene modifiers. Am J Respir Med 2003; 2: 139-56.
16. Garcia-Marcos L, Schuster A. Antileukotrienes in asthma: present situation. Expert Opin Pharmacother 2001; 2: 441-66.
17. Benrezzouk R, Terencio MC, Ferrandiz ML, Hernandez-Perez M, Rabanal R, Alcaraz MJ. Inhibition of 5-lipoxygenase activity by the natural antiinflammatory compound aethiopinone. Inflamm Res 2001; 50: 96-101.
18. Singh VP, Patil CS, Kulkarmi SK. Effect of 5-lipoxygenase inhibition on events associated with inflammatory bowel disease in rats. Indian J Exp Biol 2004; 42: 667-73.
19. Matsukawa A, Yoshimura T, Miyamoto K, Ohkawara S, Yoshinaga M. Analysis of the inflammatory cytokine network among TNF-α, IL- 1 β, IL-1 receptor antagonist, and IL-8 in LPS-induced rabbit arthritis. Lab Invest 1997; 76: 629-38.
20. Woolley DE, Tetlow LC. Mast cell activation and its relation to pro-inflammatory cytokine production in the rheumatoid lesion. Arthritis Res 2000; 2: 65-74.
21. Dinarello CA, Endres S, Meydani SN, Meydani M, Hellerstein MK. Interleukin-1, anorexia, and dietary fatty acids. Ann N Y Acad Sci 1990; 587: 332-8.
22. Dinarello CA, Endres SJ. Role for interleukin-1 in the pathogenesis of hypersensitivity diseases. J Cell Biochem 1989; 39: 229-38.
23. Offenbacher S. Periodontal diseases: pathogenesis. Ann Perio Dontol 1996; 1: 821-78.
24. Dinarello CA. Interleukin-1 and tumor necrosis factor: effecter cytokines in autoimmune diseases. Semin Immunol 1992; 4: 133-45.
25. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-16.
26. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10.
27. Thornton S, Duwel LE, Boivin GP, Ma Y, Hirsch R, et al. Association of the course of collagen- induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression. Arthritis Rheum 1999; 42:1109-18.
28. Mussener A, Litton MJ, Lindroos E, Klareskog L. Cytokine production in synovial tissue of mice with collagen-induced arthritis (CIA). Clin Exp Immunol 1997; 107:485-93.
29. Herlaar E, Brown Z. p38 MAPK signalling cascades in inflammatory disease. Mol Med Today 1999; 5: 439-47.
30. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal 2000, 12: 1-13.
31. Tyler Z, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Research 2005; 15:11-18.
32. Sweeney SE, Firestein GS. Signal transduction in rheumatoidarthritis. Curr Opin Rheumatol 2004; 16: 231-37.
33. Johnson GV, Bailey CD. The p38 MAP kinase signaling pathwayin Alzheimer's disease. Exp Neurol 2003; 183: 263-68.
34. Ford-Hutchinson AW. In: Eicosanoids and the Skin enzymatic pathways Ed: Ruzick T. Arachidonic acid metabolism. 1990; 3-22.
35. Chen J, Engle SJ, Seilhamer JJ, Tischfield JA. Cloning and recombinant expression of a novel human low molecular weight Ca(2+)-dependent phospholipase A2. J Biol Chem 1994; 269: 2365-2368.
36. Smith WL, Garavito RM, DeWitt DL. Prostaglandin Endoperoxide H Synthase (Cyclooxygenase)-l and -2. J Biol Chem 1996; 271: 33157-160.
37. Marnett LJ, Rowlinson SW, Goodwin DC, Kalgutkar AS, Lanzo CA. Arachidonic Acid Oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J Biol Chem 1999; 274: 22903-906.
38. Thuresson ED, Lakkides KM, Rieke CJ, Sun Y, Wingerd BA, Micielli R, et al. Prostaglandin Endoperoxide H Synthase-1. The functions of cyclooxygenase active site residues in the binding, positioning, and oxygenation of arachidonic acid. JBiol Chem 2001; 276: 10347-57.
39. Ogino N, Miyamoto T, Yamamoto S, Hayaishi O. Prostaglandin endoperoxide E isomerase from bovine vesicular microsomes, a glutathione-requiring enzyme. J Biol Chem. 1978; 253: 890-95.
40. Nugteren DH, Hazelhof E. Isolation and properties of intermediates in prostaglandin biosynthesis. Biochim Biophys Acta 1973; 326; 448-61.
41. Pace-Asciak CR. Oxidative biotransformations of arachidonic acid. Prostaglandins 1977; 13: 811-17.
42. Kurzorok R, Lieb C. Biological studies of human semen II the action of semen on the human uterus. Proc Soc Expt Biol 1931; 28: 268.
43. Susan MF. Prostaglandins and Cancer. Frontiers in Bioscience 1997; 2: d482-500.
44. Dinarello CA. Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases. Curr Opin Immun. 1991; 3: 941-48.
45. Oppenheim JJ, Feldmann M. Editors in: A compendium of cytokines and other mediators of host defense. Cytokine Reference, Vol I. New York Academic press 2001.
46. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immun 1996; 14: 397-440.
47. Feldmann M, Maini RN. AntiTNF-α therapy of rheumatoid arthritis: what have we learned? Annul Rev Immun 2000; 19: 163-96.
48. Evangelos TA, Brian MF, Fionula MB, Ravinder NM, Feldmann M. Cytokine and anti-cytokine biologicals in autoimmune: present and future. Cytokine and growth factor reviews 2002; 13: 299-313.
49. Dinarello CA. The biological properties of interleukin-1. (Review) Euro Cytokine Netw 1994; 5: 517-31.
50. Sims JE, Giri JG, Dower SK. Short analytical review. The two interleukin-1 receptors play different roles in IL-1 actions. Clin Immunol Immunopathol 1994; 72: 9-14.
51. Brennan FM, Chantry D, Jackson A, Maini RN, Feldmann M. Inhibitory effect of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 2: 244-7.
52. Gowen M, Wood DD, lhrie EJ, McGuire MK, Russell RG. An interleukin-1 like factor stimulates bone resorption in vitro. Nature 1983; 306: 378-80.
53. Greenfeder SA, Nunes P, Kwee L, Labow M, Chizzonite RA, Ju G. Molecular cloning and characterization of a second subunit of the interleukin-1 receptor complex. J Biol Chem 1995; 270: 13757-65.
54. Li X, Commane M, Jiang Z, Stark GR. IL-1 induced in NFκB and c-Jun N terminal kinase activation diverge at IL-1 receptor associated kinase. Proc Natl Acad Sci USA 2001: 98: 4461-65.
55. Kyosseva SV. Mitogen-activated protein kinase signaling. Int Rev Neurobiol 2004; 59: 201-20.
56. Ninomiya TJ, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K. The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signaling pathway. Nature 1999; 398: 252-6.
57. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-I receptor antagonist: role in biology. Annul Rev Immun 1998; 16: 27-55.
58. Frank MM, Fries LF. The role of complement in inflammation and phagocytosis. Immunol today 1991; 12: 322-26.
59. Smedegard G, Cui LX, Hugh TE. Endotoxin-induced shock in the rat: A role for C5a. Am J Pathol 1989; 135: 489-97.
60. Stevens JH, O'Hanley P, Shapiro JM, Mihm FG, Satoh PS, Collins JA, et al. Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest 1986; 77: 1812-16.
61. Wang Y, Rollins SA, Madri JA, Matis LA. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA 1995; 92: 8955-59.
62. Hugli TE, Muller Eberhard HJ. Anaphylatoxins: C3a and C5a. Adv Immunol 1978; 26: 1-53.
63. Hugli TE. Structure and function of the anaphylatoxins. Springer Semin. Immunopathol 1984; 7: 193-219.
64. Hugli TE, Marceau F, Lundberg C. Effects of complement fragments on pulmonary and vascular smooth muscle. Am Rev Respir Dis 1987; 135: S9-13.
65. Johnson AR, Hugh TE, Muller Eberhard HJ. Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology 1975; 28: 1067.
66. Regal JF, Hardy TM, Casey FB, Chakrin LW. C5a-induced histamine release. Species specificity. Int Arch Allergy Appl Immunol 1983; 72: 362-5.
67. Naccache PH, Volpi M, Showell HJ, Becker EL, Sha'afi RI. Chemotactic factor-induced release of membrane calcium in rabbit neutrophils. Science 1979; 203: 461-3.
68. O'Flaherty JT, Kreutzer DL, Ward PA. The influence of chemotactic factors on neutrophil adhesiveness. Inflammation 1978; 3: 37-48.
69. Perez HD. Biologically active complement (C5)-derived peptides and their relevance to disease. Crit Rev Oncol Hematol 1984; 1: 199-225.
70. Morgan EL, Thoman ML, Hoeprich PD, Hugh TE. Bioactive complement fragments in immunoregulation. Immunol Lett 1985; 9: 207-13.
71. Goldstein IM. Inflammation: Basic Principles and Clinical Correlates. Raven New York 1988; 55.
72. Montz H, Koch KC, Zierz R, Gotze O. The role of C5a in interleukin-6 production induced by lipopolysaccharide or interleukin-1. Immunology 1991; 74: 373-9.
73. Fernandez HN, Henson PM, Otani A, Hugli TE. Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J Immunol 1978; 120: 109-15.
74. Shin HS, Snyderman R, Friedman E, Mellors A, Mayer MM. Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement. Science 1968; 162: 361-63.
75. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120.
76. Chandrasekharan NV, Dai H, Roos LT, Evan-son NK, Tomsik J, Elton TS, Simmons DL. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002; 99: 13926-31.
77. Warner TD, Mitchell JA. Cyclooxygenase-3 (COX-3): Filling in the gaps toward a COX continuum? Proc Natl Acad Sci USA 2002; 99: 13371-73.
78. Eric H, Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 1206-18.
79. Wu KK. Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Mod 2003; 3:107-12.
80. Hawkey CJ. COX-2 Inhibitors. Lancet 1999; 353:307-314.
81. Cryer B, Feldman M. COX-1 and COX-2 selectivity of widely used NSAIDs. Am J Med 1998; 104: 413-21.
82. Noguchi M, Kimoto A, Kobayashi S, Yoshino T, Miyata K, Sasamata M. Effect of celecoxib, a cyclooxygenase-2 inhibitor, on the pathophysiology of adjuvant arthritis in rat. Eur J Pbarmacol 2005; 513: 229-35.
83. Davies NM, Jamali F. Selective COX-2 inhibitor cardiac toxicity: getting to the heart of the matter. J Pharma Pharmaceut Sci 2004; 7: 332-36.
84. Bresalier RS, Sandler RS, Quan H, Bolognese JA, et al. Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. N England J Med 2005; 352: 1092-102.
85. Juni P, Nartey L, Reichenbach S, Starchi S, Dippe PA. Risk of events of rofecoxib: cumulative meta analysis. Lancet 2004; 365; 2021-29.
86. Weir MR, Sperling RS, Reicin A, Gertz BJ. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J 2003; 146: 591-604.
87. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal antiinflammatory drugs and congestive heart failure out-comes in elderly patients: a population-based cohort study. Lancet 2004; 363: 1751-6.
88. Egan KM, Wang M, Fries S, Lucitt MB, Zukas AM, Pure E, et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005; 111: 334-342.
89. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective cyclooxygenase-2 inhibitors. JAMA 2001:286: 954-59.
90. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104: 2280-88.
91. Ames RS, Li Y, Sarau HM, Nuthulaganti P, Foley JJ, Ellis C, Zeng Z, et al. Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J Biol Chem 1996; 271: 20231-14.
92. Crass T, Raffetseder U, Martin U, Grove M, Klos A, Kohl J, Bautsch W. Expression cloning of the human C3a anaphylatoxin receptor (C3aR) from differentiated U-937 cells. Eur J Immunol 1996; 26: 1944-50.
93. Chenoweth DE, Hugli TE. Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 1978; 75: 3943- 47.
94. Gerard NP, Gerard C. The chemotactic receptor for human C5a anapbylatoxin. Nature 1991; 349: 614-17.
95. Wetsel RA. Structure, function and cellular expression of complement anaphylatoxin receptors. Curr Opin Immunol 1995; 7: 48-53.
96. Siciliano SJ, Rollins TE, DeMartino J, Konteatis Z, Malkowitz L, Van Riper G, et al. Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. Proc Natl Acad Sci USA 1994; 91:1214-18.
97. Czermak BJ, Sarma V, Pierson CL, Warner RL, Huber-Lang M, Bless NM, et al. Protective effects of C5a blockade in sepsis. Nat Med 1999; 5: 788-92.
98. Hatherill JR, Stephens KE, Nagao K, Ishizaka A, Wilmarth L, Wang JC, et al. Effects of anti-C5a antibodies on human polymorphonuclear leukocyte function: chemotaxis, chemiluminescence, and lysosomal enzyme release. J Biol Response. Mod 1989; 8: 614-24.
99. Pellas TC, Boyar W, van Oostrum J, Wasvary J, Fryer LR, Pastor G, Sills M, Braunwalder A, Yarwood DR, Kramer R, Kimble E, Hadala J, Haston W, Moreira-Ludewig R, Uziel-Fusi S, Peters P, Bill K, Wennogle LP. Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo. J Immunol 1998; 160: 5616-20.
100. Pellas TC, Wernnogle LP. C5a receptor antagonists. Curr Pharm Des 1999; 5:737-55.
101. Anna JS, Trent MW, Gerald H, David PF, Stephen MT. A new Small Molecule C5a Receptor Antagonist Inhibits the Reverse-Passive Arthus Reaction and Endotoxic Shock in Rats. The Journal of Immunology 2000; 164: 6560-65.
102. Angela MF, Allan KW, Natalii JP, Khe'mar Wadi S, David JC, David PF, et al. Low-Molecular-Weight Peptidic and Cyclic Antagonists of the Receptor for the Complement Factor C5a. J Med Chem 1999; 42: 1965-74.
103. Hiroshi S, Kei S, Noriko S, Sanae T, Seigo I, Mitsuharu N, Takao K. Identification of a Potent and Orally Active Non-peptide C5a Receptor Antagonist. J Biol Chem 2002; 51: 49403-07.
104. Lanza TJ, Durette PL, Rollins T, Siciliano S, Cianciarulo DN, Kobayashi SV, Caldwell CG, Springer MS, Hagmann WK. Substituted 4, 6- Diaminoquinolines as Inhibitors of C5a Receptor Binding. J Med Chem 1992; 35: 252-58.
105. Dinarello CA. Interleukin-1 and interleukin-I antagonism. Blood 1991; 77: 1627-52.
106. Gabay C. IL-1 inhibitors: novel agents in the treatment of rheumatoid arthritis. Expert Opin Inves Drugs 2000; 9: 113-27.
107. Black R A, Kronheim SR, Sleath PR. Activation of interleukin-1β by a co-induced protease. FEBS Lett 1989; 247: 386-90.
108. Thromberry NA, Howard AD, Chapman KT, Griffin PR. Inactivation of interleukin-1 beta converting enzyme by peptide (acyloxy) methylketones. Biochemistry 1994; 33: 3934-40.
109. Sleath PR, Hendrickson RC, Kronhein SR, March CJ, Black RA. Substrate specificity of the protease that processes human interleukin-1 beta. J Biol Chem 1990; 265: 14526-28.
110. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, et al. A novel heterodimeric cysteine protease is required for interleukin-l beta processing in monocytes. Nature 1992, 356: 768-74.
111. Chiou GC. Interleukin-1 blockers: a new class of nonarachidonate, nonsteroidal antiinflammatory drugs. Drugs of the Future 1999; 24: 979.
112. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993; 54: 167-227.
113. Malyak M, Guthridge JM, Hance KR, Dower SK, Freed JH, Arend WP. Characterization of a low molecular weight isoforms of IL-1 receptor antagonist. J Immunol 1998; 161: 1997-2003.
114. Arend WP. The balance between IL-1 and IL-1 Ra in disease Cytokine and growth factors reviews 2002; 13: 323-40.
115. Ator MA: Dolle RE. Current Pharmaceutical design 1995; 1: 191.
116. Graeme S, Doreen MA, Andrezj RB, Andrew JB, David WM. Peptidomimetic aminomethylene ketone inhibitors of IL-l β converting enzyme (ICE). Bioorg Med Chem Lett 1998; 8: 959-64.
117. Prasad CVC, Catherine PP, Denton H, Tina MR. Structural and stereochemical requirements of time dependent inactivators of the ICE. Bioorg Med Chem Lett 1995; 5: 315-18.
118. Todd G, Catherine PP, Gary J S, Dentone H, Dolley R E. α-((tetronolyl)oxy)- and α-(tetramoyl)-oxy)-methyl ketone inhibitors of the ICE. Bioorg Med Chem Lett 1997; 7:41-6.
119. Dolle RE, Prasad CVC, Prouty CP, Salvino J M, Awad M MA, Schmidt SJ, et al. Pyridazinodiazepines as a high-affinity, P2-P3 peptidomimetic class of interleukin-1 beta-converting enzyme inhibitor. J Med Chem 1997; 40: 1941-46.
120. Dolle RE, Prouty CP, Prasad CVC, Cook E, Saba A, Ross TM, et al. First examples of peptidomimetic inhibitors of interleukin-1 beta converting enzyme. J Med Chem 1996; 39: 2438-40.
121. Julian MCG, Michael DM, Mark AM, Keith PW, et al. Structure-based design of non-peptidic pyridone aldehydes as inhibitors of interleukin-1 β converting enzyme. Bioorg Med Chem Lett 1997; 7: 2181-86.
122. Laufersweiler MC, Wang Y, Soper DL, Suchanek MK, Fancher AN, et al. Synthesis and evaluation of tricyclic pyrrolopyrimidinones as dipeptide mimetics:Inhibition of interleukin-1 β converting enzyme. Bioorg Med Chem Lett (in press).
123. Dolle RE, Dentone H, James MR, Tine MR, Stanley JS. 3-Chloro-4- carboxamido-6-arylpyridazines as a non-peptide ICE inhibitor. Bioorg Med Chem Lett 1997; 7: 1003-06.
124. Takayuki M, Taro A, Tadaaki O, Tomoyuki K, Masao O, Hiromichi S. Synthesis and Bioactivities of Novel Pyridazine Derivatives: Inhibitors of IL-1 Beta Production. Bioorg Med Chem Lett 2001; 11: 2369-72.
125. Takayuki M, Taro A, Tomoyuki K, Masao O, Hiromichi S. Synthesis and Bioactivities of Novel 5,6-Bis(4-methoxyphenyl)-2H- pyri-dazin-3-one Derivatives: Inhibitors of Interleukin- 1 Beta (IL-1β) Production. Bioorg Med Chem Lett 2001; 11: 2373-75.
126. Laufer S, Striengel H, Alberecht W, Tollmann K. Preparation of 2-thio- substituted imidazole derivatives as immunomodulators WO 2003097633.
127. Wachter M, Beers SA. Preparation of 2-substituted imidazoles useful in the treatment of inflammatory disease WO 9903837.
128. Beers SA, Wachter M, Wu W. Preparation of substituted imidazoles useful in the treatment of inflammatory disease WO 9847892.
129. Adams J, Gallagher TF, Sisko JO, Irennegbe K, Boehm JC. Imidazole compounds useful as cytokine inhibitors US 6218537.
130. Aggarwal BB, Kohr WJ, Hass PE, Spencer SA, Henzel WJ, Bringman TS, et al. Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem 1985; 260: 2345-54.
131. Aggarwal BB, Natarajan K. Tumor necrosis factors: developments during the last decade. Eur. Cytokine Network 1996; 7: 93-124.
132. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-33.
133. Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol Supp. 1999; 26: 16-21.
134. Stocker W, Grams F, Baumann U, Reinemer P, Gomis-Ruth FX, Mckay DB, et al. The metzincins--topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci 1995,4: 823-40.
135. Hooper NM. Families of zinc metalloproteases. FEBS Lett 1994; 354:1-6.
136. McGeehan G, Becherer J, Bast R, Boyer C, Champion B, Connolly K, et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 1994; 370: 558-61.
137. Michael A, Letavic JT, Barberia TJ, Carty JR, Hardink JL, Lori L. et al. Synthesis and Biological Activity of Piperazine-Based Dual MMP-13 and TNF-α Converting Enzyme Inhibitors. Bioorg Med Chem Lett 2003; 13: 3243-46.
138. Jian JC, Nolan D, Xiaohong L, Robert LM, Keith AM, Walker JH, et al. Design and Synthesis of Orally Active Inhibitors of TNF Synthesis as Anti-rheumatoid Arthritis Drugs. Bioorg Med Chem Lett 2003; 13: 3951-54.
139. Rothenberg M, Nelson A, Hande K. New Drugs on the Horizon: Matrix Metalloproteinase Inhibitors. Oncologist 1998; 3: 271-74.
140. James H, Katherine M, Patrick M, Ildiko E, Junling Li, Lori P, et al. Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-α converting enzyme. Bioorg Med Chem Lett 2001; 11: 2907-10.
141. James JW, Duan ZL, Chu-Biao X, Xiaohua H, Jennifer LS, John J, et al. Discovery of N-Hydroxy-2-(2-oxo-3- pyrrolidinyl) acetamides as Potent and Selective Inhibitors of Tumor Necrosis Factor-α Converting Enzyme (TACE). Bioorg Med Chem Lett 2003; 13: 2035-40.
142. Toshiaki M, Shinya T, Kazunori N, Nagashige O, Masaru S, Wataru K, et al. Discovery of Novel Phosphonic Acid Derivatives as New Chemical Leads for Inhibitors of TNF-α Production. Bioorg Med Chem Lett 2002; 10: 3807-15.
143. Masaaki S, Kiriko K, Yoshimasa I, Hirosato K, Kohichiro Y. Discovery of Selective Phosphonamide-Based Inhibitors of Tumor Necrosis Factor-α Converting Enzyme. Bioorg Med Chem Lett 2003; 13: 2021-24.
144. Masakazu F, Taketsugu S, Naoko I. Synthesis and Bioactivities of Novel Bicyclic Thiophenes and 4,5,6,7- Tetrahydrothieno [2,3-c]pyridines as Inhibitors of Tumor Necrosis Factor-α (TNF-α) Production. Bioorg Med Chem Lett 2002; 12: 1897-1900.
145. Masakazu F, Tetsuya H, Naoko I. Design, Synthesis and Bioactivities of Novel Diarylthiophenes: Inhibitors of Tumor Necrosis Factor-α (TNF-α) Production. Bioorg Med Chem Lett 2002; 10: 3113-22.
146. Sterling DI. Pharmaceutical News 1996; 3: 17.
147. Sheskin J. Thalidomide in the treatment of lepra reactions. Clinical Pharmacol Ther 1965; 6: 303-06.
148. Gutierrez- Rodriguez O. Thalidomide. A promising new treatment for rheumatoid arthritis. Arthritis Rheum 1984; 27: 1118-21.
149. Sampaio EP, Samo EN, Galilly R, Cohn Z.A, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
150. Muller GW, Roger C, Shaei-Yun H, Laura GC, Lu MW, Rebecca TP, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-α production. Bioorg Med Chem Lett 1999; 9: 1625-30.
151. Michael G, Thomas H, Andrea T, Sunna H, Kurt Eger. Aza analogues of thalidomide: synthesis and evaluation as inhibitors of TNF-α production in vitro. Bioorg Med Chem Lett 2002; 9: 1059-65.
152. Satomi N. Christine L, Benjamin ET, Jun OL. Enhanced potency of perfluorinated thalidomide derivatives for inhibition of LPS-induced TNF-α production is associated with a change of mechanism of action. Bioorg Med Chem Lett 1998, 8: 1071-78.
153. Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammaliam cells. Science 1994; 265: 808-11.
154. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994: 372: 739-46.
155. Lee M, Park SC, Yang YG. Involvement of reactive oxygen species and p38 kinase in TRAIL/APO2L induced apoptosis. FEBS Lett 2002; 512: 313-18.
156. John GH, Cooper CL, Wilson B. p38 MAP kinase is involved in lipopolysaccharide induced dopaminergic neuronal cell death in rat mesencephalic neuron glia cultures. Annals of the New York Academy of Sciences 2002; 962: 332-46.
157. Werz O, Klemm J, Radmark O. p38 MAP kinase mediates stress induced leukotriene synthesis in a human B-leukocyte cell line. J Leukocyte Biol 2001; 70: 830-38.
158. Hundly T, Prasad A, Beaven MA. Elevated levels of COX-2 in antigen stimulated mast cells is associated with minimal activation of p38 MAP kinase. J Immunol 2001; 167: 1629-36.
159. Branger J, Van Den Blink B, Weijer S. Antiinflammatory effects of a p38 MAP kinase inhibitor during human endotoxemia. J Immunol 2002; 168: 4070-77.
160. Newton R, Holden N. Inhibition of p38 MAP kinase: potential as antiinflammatory agents in asthma? BioDrugs 2003; 17: 113-29.
161. Badger AM, Olivera D, Talmadge JE, Hanna N. Protective effect of SK&F 86002, a novel dual inhibitor of arachidonic acid metabolism, in murine models of endotoxin shock: inhibition of tumor necrosis factor as a possible mechanism of action. Circ Shock 1989; 27: 51.
162. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE. Pharmacologic profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase in animal models of arthritis bone resorption endotoxin shock and immune function. J Pharmacol Exp Ther 1996; 279: 1453-61.
163. Adams JL, Boehm JC. Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome p450 enzymes. Bioorg Med Chem Lett 1998; 8: 3111-16.
164. Kubo A, Imashiro R, Sakurai H. Preparation of 4-imidazolin-2-one derivatives as MAP kinase inhibitors. WO 2003035638 Al.
165. Wang Z, Canagarajah BJ, Boehm JC, Kassis S, Cobb MH, Young PR, Adam JL. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998, 6: 1117- 28.
166. Young PR, McLaughlin, Kumar S, Kassis S, Doyle ML, McNulty D, et al. Pyridinyl imidazole inhibitors of p38 mitogen activated protein kinase bind in the ATP site. J Biol Chem 1997; 272: 12116-21.
167. Laufer SA, Gerd KW, Dunja AK, Albrecht W. Novel substituted pyridinyl imidazoles as potent anticytokine agets with low activity against hepatic cytochrome P450 enzymes. J Med Chem 2003; 46: 3230-44.
168. Jerry LA, Jerey CB, Timothy FG, Should K, Edward FW, Ralph H, et al. Pyrimidinylimidazole Inhibitors of p38: Cyclic N- 1 Imidazole Substituents Enhance p38 Kinase Inhibition and Oral Activity. Bioorg Med Chem Lett 2001; It: 2867-70.
169. Jerey CB, Michael JB, Timothy FG, Should K, Stephen RJ, Jerry LA. Phenoxypyrimidine Inhibitors of p38a Kinase: Synthesis and Statistical Evaluation of the p38 Inhibitory. Potencies of a Series of 1-(Piperidin-4-y1)-4-(4-fluoroph-y1)-5-(2-ph-oxypyrimi-din-4-y1) Imidazoles. Bioorg Med Chem Lett 2001; 11: 1123-26.
170. Laufer SA, Gerd KW. From Imidazoles to Pyrimidines: New Inhibitors of Cytokine Release. J Med Chem 2002; 45: 2733-40.
171. Liverton NJ, Butcher JW, Claiborne CF, Claremon DA, Libby BE, Nguyen KT, et al. Design and synthesis of potent, selective, and orally.bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J Med Chem 1999; 42: 2180-90.
172. Alan J, Martyn LF, Frank H, Crystopher M, Iane MM, Kenneth MP, et al. RPR203494 a pyrimidine analogue of the p38 Inhibitor RPR200765A with an improved in vitro potency. Bioorg; Med Chem Left 2001; 11: 693-96.
173. Revesz L. Thiazole and imidazo[4,5-b] pyridine compound with MAP kinase inhibitory activity and their pharmaceutical use as anti inflammatory and immunosuppressams. WO 2001030778.
174. Swaminathan RN, David DW, Suresh BS, John ES, Edward AO, Cheryl DS, et al. p38MAP Kinase Inhibitors. Part 1: Design and Development of a New Class of Potent and Highly Selective In- hibitors Based on 3, 4-Dihydropyrido [3, 2-d]pyrimidone Scaffold. Bioorg Med Chem Lett 2003; 13: 273-76.
175. Luping Liu, John E, Stelmach, Swaminathan RN, Meng-Hsin C, Suresh BS, et al. SAR of 3, 4- Dihydropyrido[3,2-d]pyriniidone p38 Inhibitors. Bioorg Med Chem Lett 2003; 13: 3979-82.
176. Arzeno H, Chen JJ, Dunn P. Preparation of 7-oxopyridopyrimidines as p38 MAP kinase inhibitors. WO 2002018379 A2.
177. Mark AD, Michael AL, Kim FM, John TB, Thomas JC, Santo RC et al. Benzimidazolone p38 inhibitors. Bio2E& Med Chem Lett 2004; 14: 919-23.
178. McIntyre CJ, Gerald SP, Livertone NJ, O'Keefe S, O'Neill EA, Pang M et al. Pyridazine based inhibitors of p38 MAPK. Bioorg Med Chem Lett 2002; 12: 689-92.
179. Nuria Tamayo, Lillian Liao, Martin Goldberg, David Powers, Yan-Yan Tudor, Violets, Yu, et al. Design and synthesis of potent pyridazine inhibitors ofp38 MAP kinase. BioM Med Chem Lett 2005; 15: 2409-13.
180. Julianne AH, Florida K, Rowena DR, Peter JS, Ida I, James VP, et al. p38 Inhibitors: Piperidine- and 4-Aminopiperidine-Substituted Naphthyridinones, Quinolinones, and Dihydroquinazohnones. Bioorg Med Chem Lett 2003; 13: 467-70.
181. Achim S, Richard H, Franco DP. A novel Pd-catalyzed cyclization reaction of ureas for the synthesis of dihydroquinazolinone p38 kinase inhibitors. Bioorg Mod Chem Lett 2004; 14: 357-60.
182. John ES, Luping L, Sangita BP, James VP, Giovanna S, Suresh S, et al. Design and Synthesis of Potent, Orally Bioavailable Dihydroquinazolinone Inhibitors of p38 MAP Kinase. Bioorg Med Chem Lett 2003; 13: 277-28.
183. Jacques D, Holia HM, Robert NS, Roger AS, William JS, Uday K, et al. Synthesis and Pharmacological Characterization of a Potent, Orally Active p38 Kinase Inhibitor. Bioorg Med Chem Lett 2002: 12:1559-62.
184. Jacques D, Holia HM, Robert S, Beind R, William J, Mary KM, et al. 1-Pheny1-5-pyrazoly1 Ureas: Potent and Selective p38 Kinase Inhibitors. Bioorg Med Chem Lett 2000; 10: 2051-54.
185. Aniko MR, Jeffrey SJ, Robert D, Steve S, Hanno W, Holgar P, et al. p38 kinase inhibitor for the treatment of arthritis and osteoporosis: Thieny1, fury1 and pyrroly1 ureas. Bioorg Med Chem Lett 2001; 11: 9-12.
186. Jacques D, Robert S, Bemd R, Mary KM, Wendy L, Timothy BL, et al. Discovery of a New Class of p38 Kinase Inhibitors. Bioorg Med Chem Lett 2000; 10: 2047-50.
187. Zehong W, Jerey CB, Michael JB, Shouki K, John CL, Baoguang Z, et al. N-Phenyl-N-purin-6-yl Ureas: The Design and Synthesis of P38a MAP Kinase inhibitors. Bioorg Med Chem Lett 2003; 13:1191-94.
188. Regan J, Pargellis CA, Cirillo PF, Gilmore T, et al. The kinetics of binding to p38 MAP kinase by analogues of BIRB 796. Bioorg Med Chem Letts 2003; 13: 3101-3104.
189. Regan J, Pargellis CA, Cirfllo PF, Gilmore T, et al. SAR of p38 MAP kinase inhibitor BIRB 797. J Med Chem 2003; 46: 4676-86.
190. Pargellis CA, Tong L, Churchill L, Cirillo P, Gilmore T, Graham AG, et al. Inhibition of p38 map kinase by utilizing a novel allosteric binding site. Nat Struct Biol 2002; 9: 268-272.
191. Brown DS, Belfield AJ, Brown GR, Campbell D, Master DJ, et al. A novel
192. Leftheris K, Ahmed G, Dyckman AJ, Hussain Z, Ho K, Hynes J, et al. The Discovery of Orally Active Triaminotriazine Aniline Amides as Inhibitors of p38 MAP Kinase. J Med Chem 2004; 47: 6283-6291.
193. Kyriakis JM, Brautigan DL, Ingebritsen TS, Avruch J. p54 Micro-tubule- associated protein-2 kinase requires both tyrosine and threonine phosphorylation for activity. J Biol Chem 1991; 266: 10043-10046.
194. Barr RY, Bogoyevitch MA. The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs). Int J Biochern Cell Biol 2001; 33: 1047-1063.
195. Du L, Lyle CS, Obey TB, Gaarde WA, Muir JA, Bennett BL, et al. Inhibition of cell proliferation and cell cycle progression by specific inhibition of basal JNK activity: evidence that mitotic bcl-2 phosphorylation is JNK independent J Biol Chem 2004, 279: 11957-66.
196. Cheng Y, Zhizhin I, Perhnan RL, Mangoura D. Prolactin-induced cell proliferation in PC12 cells depends on JNK but not ERK activation. J Biol Chem 2000; 275: 23326-32.
197. Ammendrup A, Maillard A, Nielsen K, Andersen NA, Serup P, Madsen OD, et al. The JNK pathway is preferentially activated by interleukin-1 and controls apoptosis in differentiating pancreatic beta-cells Diabetes 2000; 49: 1468-76.
198. Javelaud D, Laboureau J, Gabison E, Verrecchia F, Mauviel A. Disruption of basal JNK activity differentially affects key fibroblast functions important for wound healing. J Biol Chem 2003; 278: 24624-28.
199. Higuchi H, Grambihler A, Canbay A, Brook SF, Gores GJ. Bile acids up- regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Spl. J Biol Chem 2004; 279: 51-60.
200. Fleming Y, Armstrong CG, Morrice N, Paterson A, Goodert M, Cohen P. Synergistic activation of stress-activated protein kinase 1/c-Jun terminal kinase (SAPK1/ JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7. Biochem J 2000; 352: 145-154.
201. Tibbles LA, Ing YL, Kiefer FN, Woodgett JR, Lassam. N. MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3. EMBO J 1996; 15: 7026-7035.
202. Ichijo H, Nishida E, Irie K, Dijke P, Saitoh M, Moriguchi T, et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/ JNK and p38 signaling pathways. Science 1997; 275: 90-94.
203. Renae KB, Marie AB. The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs). Int J Biochem. Cell Biol 2001; 33: 1047-1063.
204. Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR. Phosphorylation of c-jun mediated by MAP kinases. Nature 1992; 353: 670-673.
205. Cavigelli M, Dolfi F, Claret FX, Karin M. Induction of c-fins expression through JNK-mediated TCF/Elk-1phosphorylation. EMBO J 1995; 14: 5957-5964.
206. Dam HV, Wilhelm D, Herr I, Steffen A, Herrlich P, Angel P. ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents. EMBO J 1995; 14: 1798-1811.
207. Treisman R. Journey to the surface of the cell: fos regulation and the SRE. EMBO J 1995; 14:4905-4913.
208. Resnick L, Fennell M. Targeting JNK3 for the treatment of neurodegenerative disorders. Drug Discovery Today 2004; 9: 932-939.
209. Bennett BL, Satoh Y, Lewis A J. JNK: a new therapeutic target for diabetes. Curr Opin Pharmacol 2003; 3: 420-425.
210. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, et al. SP600125, and anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001; 98: 13681-13686.
211. Gaillard P, Jeanclaude-Etter I, Ardissone V, Arkinstall S, Cambet Y, Camps M, et al. Design and Synthesis of the First Generation of Novel Potent, Selective, and in vivo Active (Benzodiiazol-2-yl)-acetonitrile Inhibitors of the c-Jun N- Terminal kinase. J Med Chem 2005; 48: 4596-4607.
212. Grayshan R, French A, McKinnon AK, Hamad D, Boos GA. WO198910924,1989; Chem. Abstr 1990; 112: 216936.
213. Stocks MJ, Barber S, Ford R, Leroux F, St-Gallay S, Teague S, et al. Structure-driven HtL: Design and synthesis of novel aminoindazole inhibitors of c-Jun N-terminal kinase activity. Bioorg Med Chem Lett 2005; 15: 3459 - 3462.
214. Barnes PJ. Nuclear factor-kappa B. Int J Biochem Cell Biol 1997; 29: 867-70.
215. Aggarwal BB, Takada Y, Shishodia S. Nuclear transcription faactor NF-κB: role in biology and medicine. Ind J Expt Biol 2004; 42: 341-53.
216. Selftleben U, Karm M. The IKK/NFκB pathway. Crit Care Med 2002; 30: s18-26.
217. Karin M, Lin M. NFrB at the crossroads of life and death. Nat Immunol 2002; 3: 221-27.
218. Kumar A, Boriek AM. Mechanical stress activates the neclear factor kappa B pathway in skeletal muscle fibres: A possible role in ducherme muscular dystropy. FASEB J 2003; 17: 386-96.
219. Chen ZJ, Parent L, Maniatis T. Site specific phosphorylation of lkappaB by a novel ubiquitination dependent protem, kinase activity. Cell 1996; 84: 853-62.
220. Muller LU, Gay RE, Gay S. Role of nuclear factor kappaB in synovial inflammation. Curr Rheurnatol Ba 2002; 4: 201-07.
221. Joel LP, David Baltimore. Two pathways to NF-KappaB. Molecular Cell 2002; 10: 693-5.
222. Yamamoto Y, Gaynor R B. Therapeutic potential of inhibition of the NFκB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107: 135-42.
223. Valen G, Yan ZQ, Hansson GK. Nuclear factor kappa-B and the heart. J Am Coll Cardiol 2001; 38: 307-14.
224. Lentsch AB, Ward PA. The NFkappaBb/lkappaB system in acute inflarnmation. Arch Immunol Ther Exp (Warsz) 2000; 48: 59-63.
225. Feldmann MAE, Smith C, Bondeson J, Yoshimura S, Kiriakidis S, Monaco C, Gasparini C, Sacre S, Lundberg A, Paleolog E, Horwood NJ, Brennan FM, Foxwell BM. Is NF-kappaB a usefw therapeutic target in rheumatoid arthritis? Ann Rheum Dis 2002; 61: 13-18.
226. Miagkov AV, Kovalenko DV, Brown CE, Didsbury JR, Cogswell JP, Stimpson SA, et al. NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 1998; 95:13859-64.
227. Baldwin AS Jr. The NF-kappa B, I kappa B proteins: new discoveries and insights. Annu Rev Inummoll 1996; 14:649-83.
228. Alexei VM, Dmitry VK, Chadwick EB, John RD, John PCI, Stephen AS, et al. NF-kB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 1998; 95: 13859-64.
229. Jue DM, Jeon KI, Jeong TY. Nuclear factor kappaB (NF-kappaB) pathway as a therapeutic target in rheumatoid arthritis. J Korean Med Sci 1999; 14: 231-8.
230. Kopp E, Ghosh S. Inhibition of NF-kappaB by sodium salicylate and aspirin. Science 1994; 266: 956-59.
231. Yin MJ, Yamamoto Y, Gaynor RB. Antiinflammatory agents aspirin and sodium salicylate inhibit the activity of IkB; kinase b. Nature 1998; 396: 77-80.
232. Auphan N, Di Donato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids; inhibition of NF-κB activity through induction of IkB synthesis. Science 1995; 270:286-90.
233. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of IkB a in mediation of inummosuppression by glucocorticoids. Science 1995; 270: 283-86.
234. Moreira AL, Friedlander DR, Shif B, Kaplan G, Zagzag D. Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. J Neuro- oncol 1999; 43: 109-14.
235. Moreira AL, Corral LG, Ye W, Johnson B, Stirling D, Muller GW, Freedman VH, Kaplan G. AIDS Res. Hum. Retroviruses 1997; 13: 857-63.
236. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby, DA. Inducible cyclooxygenase may have antiinflammatory properties. Nature Med 1999, 5: 698-701.
237. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor- is a negative regulator of macrophage activation. Nature 1998, 391: 79-82.
238. Palanki MS, Gayo-Fung LM, Shevlin GI, Erdman P, Sato M, Goldman M, et al. Structure-activity relationship studies of ethyl 2-[(3-mediyl- 2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine- 5-carboxylate: an inhibitor of AP-1 and NF-κB mediated gene expression. Bioorg Med Chem Lett 2002; 12: 2573-2577.
239. Bristol-Myers Squibb Co. Method of treating inflammatory and immune diseases using 4-amino substituted imidazoquinoxaline, benzopyrazoloquinazoline, benzoimidazo-quinoxaline and benzo-imidazoquinoline inhibitors of I B kinase (IKK). WO 2002060386 2002.
240. Murata T, Shimada M, Sakakibara S, Yoshino T, Masuda T, Shintani T. Synthesis and structure activity relationships of novel IKK-b inhibitors. Part 3: Orally active anti-inflammatory agents. Bioorg Med Chem Lett 2004; 14: 4019-4022.
241. Murata T, Shimada M, Sakakibara S, Yoshino T, Kadono H, Masuda T. Discovery of Novel and Selective IKK- Serine-Threonine Protein Kinase Inhibitors. Part 1. Bioorg Med Chem Lett 2003; 13, 913-918.
242. Nagase H, Woessner JF. Matrixinetallo proteinases. J Biol Chem 1999; 274: 21491-94.
243. Kleiner DE, Steder-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999; 43: S42-S51.
244. Ravanti L, Kähäri VM. Matrix metalloproteinases in wound repair (Review). Int. J Mal Med 2000; 6: 391-407.
245. Konttinen YT, Ceponis A, Takagi M, Ainola M, Sorsa T, Sutinen ME, et al. New collagenolytic enzymes cascade identified at the pannus-hard tissue junction in rheumatoid arthritis: destruction from above. Matrix Biol 1998; 17: 585-601.
246. Ohuchi E, Imai K, Fujii Y, Sato H, Seild M, Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens; and other extracellular matrix macromolecules. J Biol Chem 1997; 272: 2446-2451.
247. Mignatti P, Rifkin DB. Plasminogen activators and matrix metallo-proteinases in angiogenesis. Enz Prot 1996; 49: 117-37.
248. Overall CM, Wiebkin OW, Thonard JC. Demonstration of tissue collagenase activity in vivo and its relationship to inflammation severity in human gingiva. J Periodontal Res 1987; 22: 81-88.
249. Yu AE, Hewitt RE, Connor EW, Stetler-Stevenson WG. Matrix metalloprotemases: novel targets for directed cancer therapy. Drugs Aging 1997; 11: 229-44.
250. Bigg HF, Rowan AD. The inhibition of metalloproteinases as a therapeutic target in rheumatoid arthritis and ostcoarthritis Curr Opin Pharmacol 2001; 1: 314-320.
251. Michael GN, Roger GB, Matthew JL, Staszek P, Neil GA, Biswanath D, et al. Development of Now Carboxylic Acid-Based MMP Inhibitors Derived from fianctionalized Propargylglycmes. J Med Chem 2001; 44:1060-71.
252. Beckett RP, Whittaker M. Matrix metalloproteinase inhibitors. Exp Opin Ther Pat 1998, 8: 259-282.
253. Bode W, Fernandez-Catalan C, Tschesche H, Grams F, Nagase H, Maskos K. Structural properties of matrix metalloproteinases. Cell Mol Life Sci 1999, 55:639-652.
254. Shapiro SD. Mighty mice: transgenic technology 'knocks out' questions of metalloproteinase function. Matrix Biol 1997, 15:527-533.
255. Leff RL. Clinical trials of a stromelysin inhibitor. Ann NY Acad Sci 1999,878:201-207.
256. Rasmussen HS, McCann PP. Matrix metalloprotemase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Therapeut 1997; 75: 69-75.
257. Valerie M, Catherine M, Martine D, William H. MMPs Inhibitors: Now Succinylhydroxamates with Selective Inhibition of MMP-2 over MMP-3. Bioorg Med Chem Lett 2003; 13: 2843-46.
258. Stanislaw P, Kelly L, McDow D, Neil GA, Biswanath D, Michael GN, et al. Design and Synthesis of Phosphinamide-Based Hydroxamic Acids as Inhibitors of Matrix Metalloproteinases. J Med Chem 1999; 42: 87-94.
259. Menyan C, Biswanath D, Stanislaw PL, Neil GA, Michael GN, Melanie VA, et al. Design and Synthesis of Piperazine-Based Matrix Metalloproteinase Inhibitors. J Med Chem 2000; 43: 369-80.
260. Aranapakam V, Grosu GT, Davis JM, Baihua Hu, Ellingboe J. Synthesis and Structure-Activity Relationship of Sulfonylhydroxamic Acids as Novel, Orally Active Matrix Metalloproteinase Inhibitors for the Treatment of Osteoarthritis. J Med Chem 2003; 46: 2361-2375.
261. Foley LH, Palermo R, Dunten P, Wang P. Novel 5,5-disubstitutedpyrimidine- 2,4,6-triones as selective MMP inhibitors. Bioorg Mod Chem Lett 200 1; 11: 969-72.
262. Blagg JA, Noe MC, Wolf-Gouveia LA, Reiter LA, Laird ER, Chang SP, et al. Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14. Bioorg Med Chem Left 2005; 15: 1807-1810.
263. Goodman and Gilman's. In: Hardman JGs. The pharmacological basis of therapeutics. New York McGraw Hills Co. 2001; 670-71.
264. Sakai A, Han J, Cato ACB, Akira S, Li JD. Glueocorticoids synergize with IL-1 β to induce TLR2 expression via MAP Kinase Phosphatase-1 -dependent dual Inhibition of MAPK JNK and p38 in epithelial cells. BMC Molecular Biology 2004; 5: 1-16.
265. Barr RK. The International Journal of BiocheMiLq and Cell Biology. 2001; 33: 1047-63.
266. Cortan RS, kumar V and Collins T. In: Robbin's Pathological basis of diseases. Philadelphia, WB Saunders Co. 2000; 67,
267. Akarca US. Gastrointestinal effects of selective and non-selective non-steroidal anti-inflammatory drugs. Curr Pharm Des 2005 11(14): 1779-93.
268. Tas SW, Remans PH, Reedquist KA, Tak PP. Signal transduction pathways and transcription factors as therapeutic targets in inflammatory disease: towards innovative antirlieurnatic therapy. Curr Phann Des 2005; 11 (5): 581-611.
269. Volin MV. Soluble adhesion molecules in the pathogenesis of rheumatoid arthritis. Curr Pharm Des 2005; 11 (5): 633-53.